Cumulus Oncology Ltd (Edinburgh, UK) identifies, evaluates and where appropriate in-licenses novel oncology assets where future value inflections are foreseen. The licensing agreement for VER250840 comes after a rigorous due diligence conducted by the Cumulus Oncology team. This encompassed an in-depth analysis of the existing data package and an evaluation of future clinical development options in molecularly-selected groups of patients, showing specific DNA repair aberrations. Cumulus Oncology will partner with DNA repair specialist, LXRepair (Grenoble, France) and AI specialist, Intelligent Omics (Nottingham, UK) to define the optimal clinical setting for VER250840.